T Cell News and Research

RSS

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Study shows how T cells detect dangerous invaders in the human body

T-cells are known to play a crucial role in the human immune system.

7 May 2021

Novel test detects HIV reservoir in patients more accurately

An innovative test that determines the quality and quantity of inactive HIV viruses in the genes of HIV patients may ultimately give scientists a better idea of effective drugs.

14 Apr 2021

Researchers use mathematical modeling to explain CAR T-cell therapy dynamics

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

26 Mar 2021

Genetically engineered immune cells deliver anticancer signal to organs to prevent metastasis

Scientists have genetically engineered immune cells, called myeloid cells, to precisely deliver an anticancer signal to organs where cancer may spread.

25 Mar 2021

Study shows SARS-CoV-2 antibodies wane at different rates

Researchers from Duke-NUS Medical School, the National Centre for Infectious Diseases (NCID), and the Agency for Science, Technology and Research (A*STAR) Infectious Diseases Labs have discovered that antibodies against SARS-CoV-2 decline at different speeds, and these antibodies last for only a few days in some people but remain for many years in other individuals.

24 Mar 2021

Study sheds light on how T cells specialize to combat pathogens

Scientists from the University of Basel have gained insights into the specialization of T cells.

11 Mar 2021

Immune cells in cerebrospinal fluid could be biomarkers to predict immunotherapy response

Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.

9 Mar 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021

Scientists map previously unknown metabolic pathways to produce memory T cell

Immunologists have plotted a previously unfamiliar biological pathway through which the immune system produces T cells that destroy viruses.

26 Feb 2021

Genes inherited from parents are responsible for severe COVID-19

For the first time, scientists have discovered the genetic predisposition of severe COVID-19 disease.

24 Feb 2021

Epigenetic therapy can boost the ability of immune killer T-cells to destroy cancer cells

Developing “super soldiers” of particular white blood cells to promote an anti-tumor reaction has been demonstrated in a series of well-designed experiments.

23 Feb 2021

New therapeutic approach to restore the effectiveness of immune cells

Prompted by the need to improve conventional treatments for people infected with the human immunodeficiency virus (HIV-1), a team from the Institut national de la recherche scientifique (INRS) has identified a therapeutic approach to restore the effectiveness of immune cells.

10 Feb 2021

Breast cancer-on-a-chip for rapid screening of immunotherapeutic drugs

There are many mechanisms by which the body responds to foreign invaders. One of these involves the T-cells of the immune system, which have a number of different proteins on their surface called "checkpoint proteins."

3 Feb 2021

New CAR T therapy could be more effective and less toxic against neuroblastoma

CAR T therapy has transformed the treatment for leukemia. Regrettably, the therapy is not effective enough to treat solid tumors, like neuroblastoma.

22 Jan 2021

Immature dendritic cells in young children can induce robust immune responses

A new study performed by scientists from Ludwig-Maximilians-Universitaet Muenchen (LMU) has demonstrated that putatively immature dendritic cells in young children can trigger powerful immune responses. The findings may result in better vaccination protocols.

21 Jan 2021

Highly developed microscopy methods can help detect antigens

Highly complicated processes constantly take place in our body to keep pathogens in check: The T-cells of our immune system are busy searching for antigens - suspicious molecules that fit exactly into certain receptors of the T-cells like a key into a lock. This activates the T-cell and the defense mechanisms of the immune system are set in motion.

22 Dec 2020

Study may lead to new approaches to protect older individuals from viruses

A drug that boosts the removal of cellular debris in immune cells may increase the protective effects of vaccines in older adults, a study published today in eLife shows.

16 Dec 2020

New combination therapy could be effective in treating aggressive cancers with common mutations

Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.

15 Dec 2020

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020